POST-TEST

Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 2 of a 3-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Which statement best characterizes overall survival (OS) outcomes observed at the 3-year follow-up with first-line nivolumab in combination with chemotherapy versus chemotherapy alone for advanced gastric cancer/gastroesophageal junction (GEJ) cancer/esophageal adenocarcinoma?**
   a. Clinically meaningful OS improvement was maintained in the PD-L1 CPS ≥5 population only
   b. Clinically meaningful OS improvement was maintained in the PD-L1 CPS ≥5 and all randomized populations
   c. Clinically meaningful OS improvement was maintained in neither the PD-L1 CPS ≥5 nor the all randomized population

2. **Tislelizumab binds to which of the following proteins?**
   a. HER2
   b. PD-1
   c. CLDN18.2
   d. TROP2

3. **The addition of tislelizumab to chemotherapy demonstrated which outcome in a Phase III trial for patients with PD-L1-positive advanced gastric/GEJ cancer?**
   a. A progression-free survival (PFS), but not an OS benefit, was observed with tislelizumab compared to placebo
   b. Both a PFS and an OS benefit were observed with tislelizumab compared to placebo
   c. No PFS or OS benefit was observed with tislelizumab compared to placebo

4. **The Phase III trial of zolbetuximab with CAPOX versus CAPOX alone as first-line therapy for patients with claudin 18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma demonstrated which outcome?**
   a. A benefit in PFS but not OS
   b. A benefit in both PFS and OS
   c. No benefit in either PFS or OS

5. **Primary and updated analyses of the Phase II single-arm trial of trastuzumab deruxtecan for patients from Western countries with HER2-positive advanced gastric or GEJ cancer demonstrated which of the following objective response results?**
   a. A confirmed objective response of 10% to 13%
   b. A confirmed objective response of 38% to 42%
   c. A confirmed objective response of 62% to 75%